Fat loss injections and Mounjaro: what the evidence shows

What the SURMOUNT-1 trial actually found

The headline evidence comes from SURMOUNT-1, a 72-week randomised trial in adults with obesity but without type 2 diabetes, published in the New England Journal of Medicine. Participants on tirzepatide 15mg lost an average of around 20–21% of their starting body weight. That figure is a mean (some lost more, some less) but the consistency across dose groups was striking: even at 5mg, average weight reduction exceeded 15%. NICE reviewed this data as part of its appraisal of tirzepatide and recommended it for NHS use in eligible adults, a decision published in late 2024 and updated in September 2025.

The trial involved 2,539 participants, a substantial randomised cohort. Calling this a small study would be wrong. And when a separate head-to-head trial (SURMOUNT-5, 2025) compared tirzepatide directly with semaglutide 2.4mg in adults with obesity, tirzepatide produced greater average weight reduction over 72 weeks. That comparison matters because both medicines are now available privately in the UK, and if you are searching for Mounjaro weight loss injections near me, it helps to know what sets each option apart before speaking to a prescriber. The honest question is which one suits a particular person, a decision that belongs with a prescriber, not a search engine.

One thing worth saying plainly: if you're reading about fat loss injections feeling a little sceptical about the numbers, that's reasonable. Weight-loss trials have a history of promising results that don't translate. The SURMOUNT programme is different in scale and rigour, but the trial setting still includes structured dietary support alongside the medicine. Real-world results vary.

The two-pathway mechanism that sets Mounjaro apart from other weight-loss injections

Mounjaro activates two gut-hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Most other injectable weight-loss medicines, including semaglutide (Wegovy), act on GLP-1 alone. Activating both pathways appears to produce a stronger signal on appetite regulation, gastric emptying and energy balance than either pathway alone, which is the leading hypothesis for why the trial results are larger. The NHS medicines page for tirzepatide gives a clear patient-level summary of how it works and what to expect.

Practically, what this means is that most people find their appetite reduces noticeably, portions feel like enough sooner, and the pull towards snacking between meals weakens. The injection is subcutaneous (into the fat layer under the skin of the abdomen, thigh, or upper arm) using a pre-filled KwikPen. Each pen contains four weekly doses. You rotate injection sites to avoid irritation. Technique matters less than consistency; the pen is designed to be used without clinical training, though your prescriber will confirm the process with you. If you want to read more about the injection itself, our guide to using the Mounjaro injections covers the practical steps in detail.

What eligibility for Mounjaro fat loss injections actually looks like

The UK licence covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes, or obstructive sleep apnoea. A lower BMI threshold of 2.5 kg/m² applies for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance. BMI alone does not guarantee a prescription, a prescriber reviews the full clinical picture, including any contraindications and current medications.

Mounjaro is not suitable during pregnancy, breastfeeding, or for anyone actively trying to conceive, and it is not licensed for people under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome) require careful discussion before treatment. On price and how private treatment is structured, the context around Mounjaro's UK pricing is worth understanding before you compare providers. The tirzepatide weight-loss injection overview covers the full licensed schedule if you want more detail on the dose steps.

Side effects, safety monitoring, and when to act quickly

The most frequently reported side effects of Mounjaro weight loss injections are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. These are most noticeable in the first days after starting or after a prescriber increases your dose, and they generally settle as your body adjusts. Slowing down titration is one of the prescriber's main tools if side effects are disruptive, never a reason to stop without speaking to your clinical team first.

On serious but less common risks: the MHRA issued a Drug Safety Update in January 2026 drawing attention to acute pancreatitis as a known, infrequent risk across GLP-1 medicines. Severe, persistent stomach pain that spreads to the back (with or without vomiting) is a sign to seek urgent medical assessment rather than wait. Gallbladder symptoms, signs of severe dehydration from prolonged vomiting or diarrhoea, and symptoms of an allergic reaction are also reasons to act promptly. Suspected side effects can be reported directly through the MHRA's Yellow Card scheme. For an overview of how different weight-loss injections compare on safety profile and evidence, that page sets it out clearly. If you're thinking about next steps, checking your eligibility with our prescribers is a good place to start.